BARD1 and hypoparathyroidism-retardation-dysmorphism syndrome: However, the efficacy of PARP inhibitor treatments in patients with BRCAness (ATM, BAP1, BARD1, BLM, BRIP1, CHEK2, FAM175A, FANCA, FANCC, NBN, PALB2, RAD50, RAD51, RAD51C, and RTEL1), or in HRD PDAC patients, remains unclear [106].